CN Patent

CN101228150B — 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的晶形

Assigned to Novartis AG · Expires 2014-10-15 · 12y expired

What this patent protects

通过各种方法制备4-甲基-N-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺游离碱及其盐的晶形。

USPTO Abstract

通过各种方法制备4-甲基-N-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺游离碱及其盐的晶形。

Drugs covered by this patent

nilotinib-hydrochloride (Nilotinib Hydrochloride) · Jan Beumer

Patent Metadata

Patent number: CN101228150B
Jurisdiction: CN
Classification: —
Expires: 2014-10-15
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.